Beta Bionics director granted 16,965 RSUs

CARNEY SEAN reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CARNEY SEAN reported acquisition or exercise transactions in this Form 4 filing.

Beta Bionics, Inc. director Sean Carney received a grant of 16,965 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan. The award was recorded at a price of $0.00 per share, bringing his direct holdings to 32,209 shares after the grant.

Insider Trade Summary

Grant/Award: 16,965 shares

Grant/Award 1 txn

Insider CARNEY SEAN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	16,965	$0.00	$0.00

Holdings After Transaction: Common Stock — 32,209 shares (Direct)

Footnotes (1)

F1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

Key Figures

RSU grant size: 16,965 shares Price per share: $0.00 per share Total holdings after grant: 32,209 shares +2 more

5 metrics

RSU grant size 16,965 shares Restricted stock unit award on May 21, 2026

Price per share $0.00 per share Stated value for the RSU grant

Total holdings after grant 32,209 shares Sean Carney direct common stock ownership post-transaction

Transaction code Code A Grant, award, or other acquisition of common stock

Transaction direction Acquire Classified as grant/award acquisition in Form 4 data

Key Terms

restricted stock unit, 2025 Equity Incentive Plan, Form 4, Grant, award, or other acquisition

4 terms

restricted stock unit financial

"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2025 Equity Incentive Plan financial

"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."

Form 4 regulatory

"After the reported transaction, Sean Carney directly holds 32,209 shares of Beta Bionics common stock as reflected in the Form 4 filing."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Grant, award, or other acquisition financial

"Transaction code A is described as Grant, award, or other acquisition."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Beta Bionics (BBNX) report for Sean Carney?

Beta Bionics reported that director Sean Carney received a grant of 16,965 shares of common stock. The award was structured as restricted stock units under the 2025 Equity Incentive Plan and increased his direct holdings to 32,209 shares following the transaction.

Was the Beta Bionics (BBNX) insider transaction a market purchase or a grant?

The transaction was a grant, not a market purchase. Sean Carney acquired 16,965 shares at $0.00 per share as a restricted stock unit award under Beta Bionics’ 2025 Equity Incentive Plan, reflecting compensation rather than an open-market buy or sell decision.

How many Beta Bionics (BBNX) shares does Sean Carney hold after this Form 4?

After the reported transaction, Sean Carney directly holds 32,209 shares of Beta Bionics common stock. This total includes the 16,965 restricted stock units granted to him on May 21, 2026 under the company’s 2025 Equity Incentive Plan as reflected in the Form 4 filing.

What is the size of the restricted stock unit award reported by Beta Bionics (BBNX)?

The restricted stock unit award consists of 16,965 shares of Beta Bionics common stock. These RSUs were granted at a stated price of $0.00 per share as equity compensation to director Sean Carney under the company’s 2025 Equity Incentive Plan.

What plan governs the recent restricted stock grant at Beta Bionics (BBNX)?

The grant is governed by Beta Bionics’ 2025 Equity Incentive Plan. Under this plan, director Sean Carney received 16,965 restricted stock units, which are reported as common stock in the Form 4 and increased his direct ownership to 32,209 shares after the award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/26/2026 - 06:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARNEY SEAN

(Last)

(First)

(Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE

CALIFORNIA

92618

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/21/2026		A		16,965⁽¹⁾	A	$0	32,209	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

	/s/ Stephen Feider, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR